fashion -WSS

fashion

author：Wikipedia 2025-10-01 02:27:25 - browse：1

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： NYC plans to house migrants on an island in the East River

WSS

Abortion pill Supreme Court ruling could impact entire drug industry

The UK government moves asylum

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Readout LOUD podcast: mifepristone case, GLP

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Vertex Pharmaceuticals may move headquarters in Boston

Walensky prepares to leave CDC — and Congress — behind

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

Psychedelics group wrestles with new pharma identity

Biden will tout long

Jerome Adams on the need for new antivirals for Covid

Abortion pill case raises question: who can sue the FDA?

State Dept. review finds Biden bears some blame for Afghanistan failures

Vertex Pharmaceuticals may move headquarters in Boston

focus

Abortion pill Supreme Court ruling could impact entire drug industry

'The Exorcist' director William Friedkin dead at 87

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Abortion pill case raises question: who can sue the FDA?

Roche subsidiary Foundation Medicine opens new headquarters

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

explore

Wikipedia

Wikipedia

entertainment